India tweaks biosimilar guidelines to narrow waivers in clinical trials

Research
Research

India has tweaked its draft of biosimilar approval guidelines and narrowed the scope to issue waivers required to run Phase III trials and rely on clinical references to biologic drugs not marketed yet in the country.

Under the purview of the Drug Controller General of India (DCGI), the Central Drugs Standard Control Organization, which worked with the country's Department of Biotechnology, released a draft in March that invited comments until April 30 on the scope of the guidelines.

The new release apparently took the comments to heart and made changes that keep the ability of regulators to waive comparative safety and efficacy studies, but in fewer situations than the earlier document in what it called “exceptional cases.”

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In May, Roche ($RHBBY) stepped up efforts to block approvals of copies of Avastin (bevacizumab) and other drugs labeled as biosimilars in India, pressing an advantage from a recent court ruling on Herceptin (trastuzumab) related to labels that cited work done by the originator.

Still, two firms--Reliance Life Sciences and Hetero Drugs--have launched biosimilars of bevacizumab in the past month that had been approved by the DCGI, though label changes were reportedly made.

But possibly in response to the Roche legal challenge, the new guidelines widened pharmacokinetic and pharmacodynamics criteria and noted confirmatory safety and efficacy studies are mandatory for mAb products.

The CDSCO had earlier noted that the guidelines do not replace existing rules under the Drugs & Cosmetics Act or any other relevant acts.

The government of Prime Minister Narendra Modi has been working for nearly two years to revise the 1940 law but has struggled to get the legislation through parliamentary committee as it grapples with evolving technological advances in drugs and devices.

India has also worked in the past year to refine informed consent procedures for clinical trials. The country has also raised the issue of the sequence of Phase III work for biologics in the guidelines to conform to the current practices.

- here are the revised guidelines

Related Articles:
India's Hetero launches Avastin biosimilar, following Reliance into the market
India to start fresh on pharma oversight by reworking 75-year-old law
India releases guidelines on biosimilar approval, manufacturing
Roche presses on biosimilar labels in India with Avastin challenge

Read more on

Suggested Articles

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.